GLPwatch
Papers (9189)
Page 29 of 154, ranked by citation count.
- Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus.
- Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system.
- Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.
- Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis.
- Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast.
- Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
- The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
- Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
- A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
- Effect of Liraglutide on Arterial Inflammation Assessed as [<sup>18</sup>F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
- Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways.
- Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
- Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
- Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
- A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
- The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide.
- Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.
- Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
- Clinical Pharmacokinetics of Semaglutide: A Systematic Review.
- Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
- Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms.
- Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
- One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.
- Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.
- GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice.
- Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
- The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.
- Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
- Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
- Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review.
- An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
- Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.
- Effects of liraglutide in hypothalamic arcuate nucleus of obese mice.
- Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β-cell mass expansion.
- Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus.
- Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.
- Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.
- Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial.
- The effect of liraglutide on endothelial function in patients with type 2 diabetes.
- Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
- The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury.
- Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice.
- Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis.
- Sustained Release Strategy Designed for Lixisenatide Delivery to Synchronously Treat Diabetes and Associated Complications.
- Exenatide-induced acute pancreatitis.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial.
- Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
- Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network.
- Longitudinal Analysis of Obesity Drug Use and Public Awareness.
- Proteasome dysfunction mediates high glucose-induced apoptosis in rodent beta cells and human islets.
- Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
- Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy.
- Reversal of Long-Term Weight Regain After Roux-en-Y Gastric Bypass Using Liraglutide or Surgical Revision. A Prospective Study.
- Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.
- Liraglutide mitigates TNF-α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women.
- As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss.